What are the Historical Developments and Current Growth Metrics of the Anti Parkinson Drugs Market?
The anti parkinson drugs market has seen considerable growth due to a variety of factors.
• The market size for anti-parkinson drugs has experienced considerable growth recently. The forecast suggests an upsurge from $10.37 billion in 2024 to approximately $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%.
Factors responsible for this progression during the historical period include an aging population, surging disease prevalence, improvements in healthcare infrastructure, and advancements in medical research.
What Does Future Hold for The Anti Parkinson Drugs Market?
The anti parkinson drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for anti-Parkinson's medications is forecasted to experience substantial expansion in the forthcoming years. It is estimated to increase to a value of $13.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%.
Factors contributing to this projected growth during the forecast period include enhanced awareness, advancements in biotechnology, and emerging markets. The future trends within the same frame include investments in research and development, the advent of personalized medicine, therapies that modify the disease course, drug repurposing, the rise of telemedicine and remote patient monitoring, the impact of biosimilars, and the role of research collaborations.
What Are The Leading Drivers Of Growth In The Anti Parkinson Drugs Market?
The escalating number of older adults and the rising instances of Parkinson's disease is anticipated to fuel the demand for the anti-Parkinson's drugs market. Parkinson's disease is predominantly observed in individuals over 60 years old. For example, in October 2022, the World Health Organization, an American health institution, reported that 1 in every 6 people globally will be aged 60 or above by the year 2030, and this figure is expected to double (reaching 2.1 billion) by 2050. Consequently, the expansion of the elderly population is catalyzing the anti-Parkinson's drugs market growth.
What Is The Segmentation Of The Global Anti Parkinson Drugs Market?
The anti-parkinson drugs market covered in this report is segmented –
1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine
Pre-Book The Anti Parkinson Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Anti Parkinson Drugs Market Landscape?
Major firms in the anti-Parkinson drugs market are concentrating their efforts on creating cutting-edge therapeutic solutions like motor fluctuations and dyskinesia with a focus on enhancing symptom management and reducing adverse effects. Motor fluctuations and dyskinesia typically make Parkinson's disease treatment more complex and have an impact on patient welfare. For example, in January 2024, AbbVie Inc., an American pharmaceutical firm, introduced PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa), the first-ever subcutaneous 24-hours infusion therapy specially designed for advanced Parkinson's disease, focuses on extreme motor fluctuations and dyskinesia when other treatments cannot provide sufficient help. This solution continuously provides levodopa, potentially maximizing 'on' time and improving symptom management.
Who Are the Key Players In The Anti Parkinson Drugs Market?
Major companies operating in the anti-parkinson drugs market include:
• GlaxoSmithKline plc
• Pfizer Inc.
• Merck Co.
• Novartis AG
• F. Hoffmann-La Roche AG
• UCB S.A
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Mylan NV
• C.H. Boehringer Sohn AG & Co. KG
• Orion Pharma Ltd.
• ACADIA Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• US WorldMeds LLC
• Zydus Lifesciences Limited
• Chemical Industrial & Pharmaceutical Laboratories Ltd.
• Strides Shasun Ltd.
• Axcan Pharma Inc.
• Upsher-Smith Laboratories LLC
• H. Lundbeck A/S
• Vertical Pharmaceuticals LLC
• Zambon SPA
• M Somerset Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• Neurocrine Biosciences Inc.
• Supernus Pharmaceuticals Inc.
What Are The Regional Insights Into The Anti Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
